| 000 | 01926 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516231155.0 | ||
| 264 | 0 | _c20150825 | |
| 008 | 201508s 0 0 eng d | ||
| 022 | _a1463-1326 | ||
| 024 | 7 |
_a10.1111/dom.12382 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aReusch, J | |
| 245 | 0 | 0 |
_aEfficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. _h[electronic resource] |
| 260 |
_bDiabetes, obesity & metabolism _cDec 2014 |
||
| 300 |
_a1257-64 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aBlood Glucose _xdrug effects |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlucagon-Like Peptide 1 _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemia _xchemically induced |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aIncretins |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMetformin _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPioglitazone |
| 650 | 0 | 4 |
_aThiazolidinediones _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aStewart, M W | |
| 700 | 1 | _aPerkins, C M | |
| 700 | 1 | _aCirkel, D T | |
| 700 | 1 | _aYe, J | |
| 700 | 1 | _aPerry, C R | |
| 700 | 1 | _aReinhardt, R R | |
| 700 | 1 | _aBode, B W | |
| 773 | 0 |
_tDiabetes, obesity & metabolism _gvol. 16 _gno. 12 _gp. 1257-64 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/dom.12382 _zAvailable from publisher's website |
| 999 |
_c24128439 _d24128439 |
||